News Release 

Abbreviated MRI outperforms 3D mammograms at finding cancer in dense breasts

ECOG-ACRIN Cancer Research Group study published in JAMA builds evidence for use of abbreviated MRI in women with dense breasts

ECOG-ACRIN Cancer Research Group


IMAGE: Dr. Comstock (Memorial Sloan Kettering Cancer Center) is the lead author of a paper in JAMA that reports that abbreviated breast MRI detected significantly more (almost 2 and a half... view more 

Credit: Memorial Sloan Kettering Cancer Center

According to a study published today in the Journal of the American Medical Association, abbreviated breast magnetic resonance imaging (MRI) detected significantly more cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breast tissue. The study compared the 10-minute MRI exam to 3-D mammography, in women with dense breasts, because the ability of mammography to detect breast cancer is limited in these women. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) designed and conducted the study (EA1141) with funding from the National Cancer Institute, part of the National Institutes of Health, and Bracco Diagnostics Inc. (Monroe Township, NJ).

According to Christopher E. Comstock, MD, the publication's lead author, "When screening women at average risk with dense breasts, we found that abbreviated breast MRI detected significantly more (almost two and a half times as many) breast cancers as 3-D mammography. We also found that the abbreviated breast MRI was well tolerated by women, with very few side effects."

Dr. Comstock is Attending Radiologist and Director of Breast Imaging Clinical Trials at Memorial Sloan Kettering Cancer Center and Imaging Chair for ECOG-ACRIN's Breast Cancer Committee. Study leadership included breast cancer researchers from Memorial Sloan Kettering Cancer Center, University Hospital of RWTH Aachen, University of Chicago, University of Pennsylvania and the Department of Biostatistics and Center for Statistical Sciences at Brown University School of Public Health.

Despite current screening methods, over 40,000 women die each year from breast cancer. The ability of mammography to detect breast cancer is especially limited in women with dense breast tissue. Having dense breasts is not an abnormal condition; in fact, about half of all women over the age of 40 have dense breasts.

Breast MRI is a screening test that uses radio waves to capture images following intravenous injection of contrast dye. Because it is not limited by breast density, MRI offers the highest cancer detection rate of all breast imaging modalities. However, breast MRI is more expensive than a mammogram, takes longer to perform (45 minutes compared to about 15 minutes for a mammogram) and requires an injection.

Although most evidence exists for using MRI to screen the small proportion of women at very high risk of breast cancer, there is accumulating evidence, pioneered by Christiane K. Kuhl, MD, PhD (Chairman of Radiology at University Hospital Aachen and the publication's senior author), that the higher sensitivity of MRI is also seen in women at average risk.

As Dr. Comstock explained, "Although MRI is undoubtedly the most sensitive test for detecting breast cancer, it is not being used to screen the large number of average-risk women with dense breasts due to its high cost and time to perform. Abbreviated breast MRI is a 10-minute test that reduces the complexity and cost of MRI by shortening the time it takes to perform and interpret the exam. The EA1141 results will hopefully give far more women access to this powerful tool in the fight against breast cancer."

The EA1141 study compared the diagnostic performance of abbreviated breast MRI to 3-D mammography in screening average-risk women with dense breasts for breast cancer.

Women were eligible to participate in the study if they were between the ages of 40 and 75, had dense breasts on their prior mammogram, and did not currently have breast cancer or any clinical symptoms. This analysis pertains to 1,444 trial participants, all of whom were screened with both 3-D mammography and abbreviated MRI within 24 hours. The images were interpreted independently by two different board-certified breast radiologists who remained blinded to the results of the other modality.

Participants were screened twice in the study, first as a baseline and again after one year, and are being followed for three additional years. Enrollment took place over 11 months (December 2016 - November 2017) at 47 centers in the US and one in Germany. The US centers are a mixture of academic, community hospital, and private institutions throughout the country.

In the first year of the study, 23 women were diagnosed with breast cancer. The abbreviated MRI detected 22 out of the 23 women with breast cancer, while the 3-D mammogram detected only nine out of the 23 women. Abbreviated MRI detected all of the cancers found on 3-D mammography except for one early stage cancer. At the same time, abbreviated MRI found an additional 10 invasive breast cancers, including three high-grade cancers, which were not detected on 3-D mammography.

There were no patients with interval cancers, which are cancers detected within 12 months after a screening exam interpreted as normal. However, the abbreviated MRI led to slightly more false-positive results, including recommendations for biopsies of findings that turned out not to be cancer.

The EA1141 study looked solely at women with dense breasts. It provides promising results for abbreviated MRI, and may ultimately help better screen women with dense breasts for cancer. The study did not attempt to provide cancer mortality information.

According to Dr. Comstock, "While these early results are promising, further studies are needed to evaluate the cost-effectiveness of widespread screening with abbreviated breast MRI and its impact on reducing breast cancer mortality. Currently, only a few centers offer abbreviated breast MRI and it is not covered by insurance. Our hope is that study EA1141 will provide the impetus for more centers to provide this new test and that insurers will see its benefit to improve early detection of breast cancer."


The publication title is "Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women with Dense Breasts Undergoing Screening."

The federal record for study EA1141 on is NCT02933489.

About the ECOG-ACRIN Cancer Research Group

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. ECOG-ACRIN comprises nearly 1100 member institutions in the United States and around the world. Approximately 12,000 physicians, translational scientists and associated research professionals from the member institutions are involved in Group research, which is organized into three scientific programs: Cancer Control and Outcomes, Therapeutic Studies, and Biomarker Sciences. ECOG-ACRIN is supported primarily through National Cancer Institute research grant funding, but also receives funding from private sector organizations through philanthropy and collaborations. Its headquarters are in Philadelphia, Pa. For more information, visit, follow us on Twitter @eaonc, Facebook, and LinkedIn, or call 215.789.3631.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.